-
公开(公告)号：US20230203037A1
公开(公告)日：2023-06-29
申请号：US18067387
申请日：2022-12-16
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Sharon MATES , Peng LI , Lawrence P. WENNOGLE , Robert DAVIS
IPC: C07D471/16 , C07D471/14 , A61K45/06 , C07B59/00 , A61P25/24 , A61P25/22 , A61P25/18 , A61K31/4985
CPC classification number: C07D471/16 , C07D471/14 , A61K45/06 , C07B59/002 , A61P25/24 , A61P25/22 , A61P25/18 , A61K31/4985
Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
-
公开(公告)号：US20220296591A1
公开(公告)日：2022-09-22
申请号：US17832282
申请日：2022-06-03
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Wei YAO , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
IPC: A61K31/4985 , A61P25/36 , A61P23/00 , A61K9/00 , A61K9/16 , A61K31/137 , A61K31/485 , A61K45/06
Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
-
公开(公告)号：US20210371421A1
公开(公告)日：2021-12-02
申请号：US17405736
申请日：2021-08-18
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Sharon MATES , Robert DAVIS , Kimberly VANOVER , Lawrence WENNOGLE
IPC: C07D471/14 , A61K45/06 , A61K31/5383 , A61K31/4985 , A61P25/28 , C07D471/16 , A61K31/445
Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
-
公开(公告)号：US20210163481A1
公开(公告)日：2021-06-03
申请号：US16634059
申请日：2018-07-20
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Hailin ZHENG , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
-
公开(公告)号：US20200017499A1
公开(公告)日：2020-01-16
申请号：US16585251
申请日：2019-09-27
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Sharon MATES , Robert DAVIS , Kimberly VANOVER , Lawrence WENNOGLE
IPC: C07D471/14 , A61K45/06 , A61K31/5383 , A61K31/4985 , C07D471/16 , A61K31/445
Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
-
Patent Agency Ranking
公开(公告)号：US20190328745A1
公开(公告)日：2019-10-31
申请号：US16507956
申请日：2019-07-10
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Kimberly VANOVER , Peng LI , Sharon MATES , Robert DAVIS , Lawrence P. WENNOGLE
IPC: A61K31/5383 , A61K9/00 , A61K9/51 , A61K31/4985 , A61K45/06
Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
-
公开(公告)号：US20240208974A1
公开(公告)日：2024-06-27
申请号：US18601923
申请日：2024-03-11
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Sharon MATES , Robert DAVIS , Kimberly VANOVER , Lawrence WENNOGLE
IPC: C07D471/14 , A61K31/445 , A61K31/4985 , A61K31/5383 , A61K45/06 , A61P25/28 , C07D471/16
CPC classification number: C07D471/14 , A61K31/445 , A61K31/4985 , A61K31/5383 , A61K45/06 , A61P25/28 , C07D471/16
Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
-
公开(公告)号：US20240059687A1
公开(公告)日：2024-02-22
申请号：US18451465
申请日：2023-08-17
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Hailin ZHENG , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
-
公开(公告)号：US20230181576A9
公开(公告)日：2023-06-15
申请号：US17015883
申请日：2020-09-09
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Wei YAO , Peng LI , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
IPC: A61K31/4985 , A61P25/00 , C07D471/16 , A61K9/00 , A61K9/16 , A61K45/00 , C07D241/40 , A61K31/445 , A61K45/06
CPC classification number: A61K31/4985 , A61P25/00 , C07D471/16 , A61K9/0019 , A61K9/16 , A61K45/00 , C07D241/40 , A61K31/445 , A61K45/06
Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
-
公开(公告)号：US20190298730A1
公开(公告)日：2019-10-03
申请号：US16443240
申请日：2019-06-17
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Kimberly VANOVER , Peng LI , Sharon MATES , Robert DAVIS , Lawrence P. WENNOGLE
IPC: A61K31/5383 , A61K31/4985 , A61K9/00 , A61K45/06 , A61K9/51
Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.019 seconds)
